Barinthus Biotherapeutics (BRNS) Current Assets (2020 - 2026)

Barinthus Biotherapeutics has reported Current Assets for 7 years, with the latest figure at $72.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 33.87% year-over-year to $72.7 million; the trailing twelve-month figure through Mar 2026 stood at $72.7 million (down 33.87% YoY), and the FY2025 full-year result was $77.8 million, down 38.14% from the prior year.
• Current Assets for Q1 2026 stood at $72.7 million, down from $77.8 million in the prior quarter.
• The five-year high for Current Assets was $230.8 million in Q1 2022, with the low at $72.7 million in Q1 2026.
• Historically, Current Assets has averaged $152.1 million across 5 years, with a median of $143.1 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets surged 41.27% — and 2025, when it sank 38.14%.
• Barinthus Biotherapeutics' Current Assets stood at $213.0 million in 2022, then declined by 26.35% to $156.9 million in 2023, then slipped by 19.86% to $125.7 million in 2024, then sank by 38.14% to $77.8 million in 2025, then dropped by 6.59% to $72.7 million in 2026.
• The last three Current Assets figures came in at $72.7 million (Q1 2026), $77.8 million (Q4 2025), and $86.8 million (Q3 2025), per Business Quant data.